公开(公告)号：ES2375823T3

公开(公告)日：2012-03-06

申请号：ES06009072

申请日：2000-06-08

Applicant: VERTEX PHARMA

Inventor： HALE MICHAEL ,  TUNG ROGER ,  PRICE STEPHEN ,  WILKES ROBIN DAVID ,  SCHAIRER WAYNE ,  JARVIS ASHLEY NICHOLAS ,  SPALTENSTEIN ANDREW ,  FURFINE ERIC STEVEN ,  SAMANO VICENTE ,  KALDOR ISTVAN ,  MILLER JOHN ,  BRIEGER MICHAEL STEPHEN

IPC: C07C311/16 ,  C07D317/62 ,  A61K20060101 ,  A61K31/34 ,  A61K31/343 ,  A61K31/352 ,  A61K31/36 ,  A61K31/5377 ,  A61K45/06 ,  A61P20060101 ,  A61P31/12 ,  A61P31/18 ,  A61P43/00 ,  C07C20060101 ,  C07C311/18 ,  C07C311/29 ,  C07D20060101 ,  C07D317/46 ,  C07D407/12 ,  C07D493/04

Abstract: Un compuesto seleccionado de los números de compuestos: 5a, 5b, 5c, 5d, 5e, 5f, 5g, 10-21, 58, 67, 68 y 328, en donde dicho compuesto tiene la estructura:**Fórmula**

公开(公告)号：AT534622T

公开(公告)日：2011-12-15

申请号：AT06009072

申请日：2000-06-08

Applicant: VERTEX PHARMA

Inventor： HALE MICHAEL ,  TUNG ROGER ,  PRICE STEPHEN ,  WILKES ROBIN DAVID ,  SCHAIRER WAYNE ,  JARVIS ASHLEY NICHOLAS ,  SPALTENSTEIN ANDREW ,  FURFINE ERIC STEVEN ,  SAMANO VICENTE ,  KALDOR ISTVAN ,  MILLER JOHN ,  BRIEGER MICHAEL STEPHEN

IPC: C07C311/16 ,  C07D317/62 ,  A61K20060101 ,  A61K31/34 ,  A61K31/343 ,  A61K31/352 ,  A61K31/36 ,  A61K31/5377 ,  A61K45/06 ,  A61P20060101 ,  A61P31/12 ,  A61P31/18 ,  A61P43/00 ,  C07C20060101 ,  C07C311/18 ,  C07C311/29 ,  C07D20060101 ,  C07D317/46 ,  C07D407/12 ,  C07D493/04

Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.